WO2013152315A1 - Composition de pesticide pour application locale contenant un pyréthroïde et une lactone macrocyclique - Google Patents

Composition de pesticide pour application locale contenant un pyréthroïde et une lactone macrocyclique Download PDF

Info

Publication number
WO2013152315A1
WO2013152315A1 PCT/US2013/035498 US2013035498W WO2013152315A1 WO 2013152315 A1 WO2013152315 A1 WO 2013152315A1 US 2013035498 W US2013035498 W US 2013035498W WO 2013152315 A1 WO2013152315 A1 WO 2013152315A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
spot
pyrethroid
growth regulator
macrocyclic lactone
Prior art date
Application number
PCT/US2013/035498
Other languages
English (en)
Inventor
Larry Nouvel
Donald Kelley
Original Assignee
Sergeant's Pet Care Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sergeant's Pet Care Products Inc. filed Critical Sergeant's Pet Care Products Inc.
Publication of WO2013152315A1 publication Critical patent/WO2013152315A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof

Definitions

  • the present invention relates to a spot-on or pour-on pesticide composition
  • a spot-on or pour-on pesticide composition comprising a pyrethroid and a macrocyclic lactone selected from an avermectin, ivermectin, selamectin, moxidectin, milbemycin, and any combination thereof, which combinations are useful in the treatment or prevention of heartworm infections, tick and flea infestations, flea allergy dermatitis, ear mites and sarcoptic mange in animals, specifically dogs.
  • Various embodiments of the present invention may further additionally include fipronil and/or an insect growth regulator.
  • Spot-on compositions that have been previously developed incorporate a multitude of pesticide agents.
  • Common agents include arylpyrazole derivatives, insect growth regulators, pyrethroids, nodulisporic acid derivatives, neonicotinoids, formamides, avermectins, and the like. All of the compounds listed herein have different mechanisms of action, and accordingly treat and prevent infestation in different manners. Consequently, the various compounds also have a variety of different adverse effects associated with treatment.
  • the various agents may be combined in a variety of concentrations.
  • the spot-on treatments known within the art generally have a prolonged period of action before the active ingredient(s) effectively eliminates the target pest.
  • insect growth regulators i.e. juvenile hormone mimetics
  • additional time is required to kill all pests, which leads to additional time in which the animal host, as well as all other animals and humans, must suffer the effects of the infestation.
  • quick-acting agents such as the arylpyrazole derivative known as fipronil, which causes hyperexcitation of the pest leading to its death, have a prolonged onset of action. Generally, it may take multiple hours for quick-acting agents to provide symptomatic relief to the host animal.
  • the invention relates to novel spot-on compositions for treating and preventing of heartworm infections, tick and flea infestations, flea allergy dermatitis, ear mites and sarcoptic mange in animal, as well as a method of killing pests comprising applying the compositions to a host animal, specifically a mammal.
  • the spot-on insecticidal compositions of the current invention comprise pyrethroid and macrocyclic lactone components, and may additionally include fipronil and/or an insect growth regulator.
  • the macrocyclic lactone may be selected from the group consisting of avermectin, ivermectin, selamectin, moxidectin, milbemycin, and any combination thereof.
  • compositions of the present invention further comprise a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce or eliminate the paresthesia caused by the pyrethroid to the animal.
  • One embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 0.25% and about 60% (w/w) pyrethroid, between about 0.01% and about 10% (w/w) macrocyclic lactone, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate, and combinations thereof to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of the spot-on composition includes between about 10% and about 45% (w/w) pyrethroid, between about 0.1% and about 8% (w/w) macrocyclic lactone, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the first embodiment of the present invention includes between about 15% and about 30% (w/w) pyrethroid, between about 0.2% and about 6% (w/w) macrocyclic lactone, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is ivermectin.
  • a second embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 0.25% and about 60% (w/w) pyrethroid, between about 0.01% and about 10% (w/w) macrocyclic lactone, between about 1% and about 20% (w/w) insect growth regulator, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 10% and about 45% (w/w) pyrethroid, between about 0.1% and about 8% (w/w) macrocyclic lactone, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 15% and about 30% (w/w) pyrethroid, between about 0.2% and about 6% (w/w) macrocyclic lactone, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is ivermectin.
  • a third embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 0.25% and about 60% (w/w) pyrethroid, between about 0.01% and about 10% (w/w) macrocyclic lactone, between about 1% and about 20% (w/w) insect growth regulator, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 10% and about 45% (w/w) pyrethroid, between about 1.5% and about 6% (w/w) macrocyclic lactone, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 15% and about 30% (w/w) pyrethroid, between about 2% and about 4% (w/w) macrocyclic lactone, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is moxidectin.
  • a fourth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 0.25% and about 60% (w/w) pyrethroid, between about 0.01% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 1% and about 20% (w/w) insect growth regulator, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 10% and about 45% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 15% and about 30% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactones preferred in this embodiment are selected from the group consisting of ivermectin, selamectin, moxidectin, milbemycin, and combinations thereof.
  • a fifth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 0.25% and about 60% (w/w) pyrethroid, between about 0.01% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 15% and about 45% (w/w) novaluron, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 10% and about 45% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 20% and about 40% (w/w) novaluron, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 15% and about 30% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 15% and about 35% (w/w) novaluron, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactones preferred in this embodiment are selected from the group consisting of ivermectin, selamectin, moxidectin, milbemycin, and combinations thereof.
  • a sixth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 1% and about 20% (w/w) pyrethroid, between about 1% to about 20% (w/w) fipronil, between about 0.01% and about 10% (w/w) macrocyclic lactone, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of the spot-on composition includes between about 2% and about 10% (w/w) pyrethroid, between about 0.01% and about 0.2% (w/w) macrocyclic lactone, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the first embodiment of the present invention includes between about 4% and about 6% (w/w) pyrethroid, between about 0.05% and about 0.1% (w/w) macrocyclic lactone, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is ivermectin.
  • a seventh embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 1% and about 20% (w/w) pyrethroid, between about 1% to about 20% (w/w) fipronil, between about 0.01% and about 10% (w/w) macrocyclic lactone, between about 1% and about 20% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the
  • this embodiment of present composition includes between about 2% and about 10% (w/w) pyrethroid, between about 0.01% and about 0.2% (w/w) macrocyclic lactone, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 4% and about 6% (w/w) pyrethroid, between about 0.05% and about 0.1% (w/w) macrocyclic lactone, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is ivermectin.
  • An eighth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 1% and about 20% (w/w) pyrethroid, between about 1% to about 20% (w/w) fipronil, between about 0.01% and about 10% (w/w) macrocyclic lactone, between about 1% and about 20% (w/w) insect growth regulator, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia- reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 2% and about 10% (w/w) pyrethroid, between about 1.5% and about 6% (w/w) macrocyclic lactone, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 4% and about 6% (w/w) pyrethroid, between about 2% and about 4% (w/w) macrocyclic lactone, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactone preferred in this embodiment is moxidectin.
  • a ninth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 1% and about 20% (w/w) pyrethroid, between about 1% to about 20% (w/w) fipronil, between about 0.01% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 1% and about 20% (w/w) insect growth regulator, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 2% and about 10% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 4% and about 15% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 4% and about 6% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 7% and about 11% (w/w) insect growth regulator, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactones preferred in this embodiment are selected from the group consisting of ivermectin, selamectin, moxidectin, milbemycin, and combinations thereof.
  • a tenth embodiment of the current invention relates to a spot-on composition
  • a spot-on composition comprising between about 1% and about 20% (w/w) pyrethroid, between about 1% to about 20% (w/w) fipronil, between about 0.01% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 15% and about 45% (w/w) insect growth regulator novaluron, and a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof, wherein the paresthesia-reducing agent is present in an amount effective to reduce the paresthesia caused by the pyrethroid to an animal.
  • this embodiment of present composition includes between about 2% and about 10% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 20% and about 40% (w/w) novaluron, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on composition of the present invention includes between about 4% and about 6% (w/w) pyrethroid, between about 0.05% and about 10% (w/w) of a combination of two or more macrocyclic lactones, between about 25% and about 35% (w/w) novaluron, and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the macrocyclic lactones preferred in this embodiment are selected from the group consisting of ivermectin, selamectin, moxidectin, milbemycin, and combinations thereof.
  • the present invention further provides a method of eliminating and preventing heartworms, pest pupae and adults infestations on an animal, specifically a dog, the method comprising administering a localized cutaneous application of a spot-on composition of the present invention between the two shoulders of the animal in a volume sufficient to deliver a dose of the active components ranging from about 0.5 mg/kg to about 10 mg/kg of animal body weight.
  • compositions provided herein are spot-on pesticide compositions that utilize combinations of certain active compounds to treat heartworm, insect, parasite, or tick and flea infestation of animals, specifically mammals (preferably dogs and cats), and also prevent future infestations by prolonged treatment efficacy that can last up to three months.
  • the compositions exterminate existing pests, and prevent those pests that survive from developing and reproducing.
  • the compositions halt the growth cycle and prevent pests from laying additional eggs.
  • the compositions of the current invention are useful in the treatment of many pests, especially heartworms, adult fleas and ticks, flea eggs and larvae, ear mites and sarcoptic mange found on domesticated animals.
  • compositions include low concentrations of a pyrethroid, a macrocyclic lactone, and may further comprise an additional pesticide (e.g., an insect growth-regulating compound, an N-arylpyrazole, or the like).
  • an additional pesticide e.g., an insect growth-regulating compound, an N-arylpyrazole, or the like.
  • the present invention is based in part on the finding that treatment of a host animal with compositions comprising a combination of a pyrethroid and a macrocyclic lactone results in dramatically higher kill rates within a shorter period of time of treatment than does treatment with an insect growth regulator, alone or combined, without the addition of a pyrethroid.
  • the present invention further comprises a novel paresthesia-reducing agent to reduce the paresthesia caused by the pyrethroid to an animal, wherein the paresthesia- reducing agent is selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the spot-on compositions of the present invention comprise a pyrethroid compound.
  • pyrethroids are a class of synthetic insecticides that are related to the naturally-occurring pyrethrins. Pyrethroids tend to be more effective than the natural pyrethrins, and less toxic to mammals.
  • Pyrethroids are axonic poisons that work by keeping the sodium channels open in the neuronal membranes.
  • the sodium channel consists of a membrane protein with a hydrophilic interior which permits sodium ions to enter and exit the membrane. When the sodium channels are kept open, the influx of sodium ions results in hyperexcitation and the pest becomes paralyzed.
  • Suitable non-limiting examples of pyrethroids that may be used in the present invention include cyphenothrin, permethrin, cypermethrin, etofenprox, fenvalerate, cyfluthrin, and the like.
  • the pyrethroid comprises between about 0.25% and about 60% (w/w) of the total weight of the spot-on composition. In some embodiments, the pyrethroid comprises about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.25% (w/w), or any range thereof, of the spot-on composition.
  • the amount of a pyrethroid present in the spot-on composition may range from between about 10% to about 45% (w/w) of the total composition, and preferably ranges from about 15% to about 30% (w/w).
  • the amount of pyrethroid present in the spot-on composition effective for the treatment of pest infestations in mammals is about 20% (w/w) of the total composition.
  • the spot-on compositions of the present invention also comprise a macrocyclic lactone.
  • Macrocyclic lactones are effective agents against both endoparasites and ectoparasites.
  • Macrocyclic lactones are natural fermentation products of the fungus-like Streptomyces bacteria, including, but not limited to avermectin, abamectin, moxidectin, doramectin, ivermectin, and milbemycin, and the like, which share in common a large complex macrocyclic backbone.
  • the macrocyclic lactone is an avermectin compound.
  • Avermectins are a group of chemically related potent anthelmintics and insecticides that are derivatives of a series 16-membered macrocyclic lactone.
  • the naturally occurring avermectin compounds are produced by fermenting Streptomyces avermitilis, a soil actinomycete.
  • the avermectin compounds are capable of blocking the transmittance of electrical activity in nerves and muscle cells by stimulating the release and binding of gamma-aminobutyric acid (GABA) at nerve endings.
  • GABA gamma-aminobutyric acid
  • Different avermectins have a major (Bi a -component) and minor (Bi b -component) component usually in ratios of 80:20 to 90: 10.
  • Anthelmintics derived from the avermectins include ivermectin, selamectin, doramectin, and abamect
  • the avermectin compound typically comprises between about 0.01% and about 10% (w/w) of the spot-on composition.
  • the avermectin comprises about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.5%, 0.25%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, or 0.01% (w/w) of the spot-on composition.
  • the amount of avermectin compound present in the spot-on composition may range from between about 0.01% to about 8% (w/w) of the total composition, and preferably ranges from about 0.05% to about 5% (w/w).
  • the amount of avermectin compound present in the spot-on composition may range from about 0.1% to about 5% (w/w) of the total composition.
  • the amount of avermectin compound present in the spot-on composition may range from about 0.2% to about 1.5% (w/w) of the total composition.
  • the amount of avermectin compound present in the spot-on composition may range from between about 1.5% to about 3% (w/w) of the total composition.
  • the amount of avermectin compound present in the spot-on composition may range from between about 0.06% to about 0.09% (w/w) of the total composition.
  • the avermectin in the composition is ivermectin.
  • Ivermectin is the combination of two dehydrogenated avermectins (22,23-dihydroavermectin Bla + 22,23-dihydroavermectin Bib), and is a broad- spectrum antiparasitic avermectin medicine.
  • the avermectin compound present in the composition is selamectin (C43H63N011 ).
  • Selamectin disables parasites by replacing glutamate in their muscle synapses.
  • Selamectin interferes the interaction between glutamate and its receptors that open chloride channels into the muscle, and activates the chloride current without desensitization, allowing chloride ions to enter the nerve cells and causing neuromuscular paralysis, impaired muscular contraction, and eventual death of parasites.
  • the spot-on pesticide composition of the current invention may comprise a macrocyclic lactone that is a moxidectin or a milbemycin compound.
  • Moxidectin is a semisynthetic derivative of nemadectin which is produced by fermentation by Streptomyces cyano-griseus. Both moxidectin and milbemycin treat and control some of the most common internal and external parasites by selectively binding to parasites' glutamate-gated chloride ion channels. These channels are vital to the function of invertebrate nerve and muscle cells. When moxidectin or milbemycin binds to the channels, it disrupts neurotransmission, resulting in paralysis and death of the parasite.
  • the moxidectin compound typically comprises between about 1% and about 5% (w/w) of the spot-on composition.
  • the moxidectin comprises about 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, or 1% (w/w) of the spot-on composition.
  • the amount of a moxidectin present in the spot-on composition may range from between about 1% to about 4.5% (w/w) of the total composition, and preferably ranges from about 1.5% to about 4% (w/w).
  • the amount of a moxidectin present in the spot-on composition may range from about 2% to about 5% (w/w) of the total composition. In a further embodiment, the amount of a moxidectin present in the spot-on composition may range from about 2% to about 4% (w/w) of the total composition.
  • milbemycin may be used and typically comprises between about 1% and about 5% (w/w) of the spot-on composition.
  • the milbemycin comprises about 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, or 1% (w/w) of the spot-on composition.
  • the amount of a milbemycin present in the spot-on composition may range from between about 1% to about 4.5% (w/w) of the total composition, and preferably ranges from about 1.5% to about 4% (w/w).
  • the amount of a milbemycin present in the spot-on composition may range from about 2% to about 5% (w/w) of the total composition.
  • the amount of a milbemycin present in the spot-on composition may range from about 2% to about 4% (w/w) of the total composition.
  • the compositions of the present invention may include at least one macrocyclic lactone, or alternatively, may comprise a combination of two or more macrocyclic lactones.
  • the spot-on pesticide compositions of the current invention may additionally include an insect growth regulator (IGR). IGRs are not effective in killing preexisting pests; they prevent reproduction and further infestation.
  • IGR is generally a compound that is capable of disrupting the growth and development of pest species, so that the pest cannot mature and reproduce.
  • the IGR typically comprises less than about 20% (w/w) of the total weight of the spot-on composition.
  • the IGR comprises about 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, or 0% (w/w) of the spot-on composition.
  • the amount of IGR present in the spot-on composition may range from between 1% to about 20% (w/w) of the total composition weight, and preferably the IGR ranges from between about 2% to about 15% (w/w) of the total composition.
  • the amount of IGR present in the spot-on composition may range from about 4% to about 12% (w/w) of the total composition.
  • the amount of IGR present in the spot-on composition may range from about 7% to about 14% (w/w) of the total composition. In still another embodiment, the amount of IGR may range from between about 8% to about 12% (w/w) of the total composition. In an additional embodiment, the amount of IGR may range from between about 2% to about 9% (w/w) of the total composition. In a further embodiment, the amount of IGR may range from between about 3% to about 5% (w/w) of the total composition. IGRs may include, but are not limited to juvenile hormone mimics, chitin synthesis inhibitors, and the like.
  • insect growth regulators include bistrifluron, buprofezin, chlorfluazuron, cyromazine, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, penfluron, teflubenzuron, triflumuron, epofenonane, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen, triprene, and combinations thereof.
  • the insect growth regulator is S- methoprene.
  • methoprene is a racemic mixture of the R- and S- enantiomers of the compound, however, only the S-enantiomer is active as a juvenile hormone analog.
  • a juvenile hormone analog exerts a therapeutic effect by mimicking the natural juvenile hormones found within pests. Juvenile hormone must be absent for a pupa to molt to an adult, so methoprene treated larvae are unable to successfully develop from pupa to an adult pest. This action breaks the natural life cycle of the pest, preventing it from maturing and reproducing.
  • S-methoprene is also known as isopropyl (2E, 4E, 7S)-l l-methoxy-3,7,l l-trimethyl-2,4-dodecadienoate.
  • S- methoprene is available in a variety of commercial products and is useful in controlling long- term pest infestation, while other active components are primarily effective in the immediate, short-term elimination of pests.
  • the pest kill time for treatment with S-methoprene will vary depending on the typical duration of life for the species being treated. Unlike some other compounds, S-methoprene is generally considered non-toxic to humans, which has led to its use in the treatment of well cisterns and a number of food items, including meat, milk, mushrooms, peanuts, rice, and cereals.
  • the concentration of S-methoprene present in the spot-on composition effective for the treatment of pest infestations in animals is about 8.8% (w/w) of the total composition.
  • the insect growth regulator may be the juvenile hormone analog pyriproxyfen, also known as 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether and NylarTM.
  • the amount of pyriproxyfen present in the spot-on composition effective for the treatment of pest infestations in animals is about 2% (w/w) of the total composition.
  • the insect growth regulator may be the novaluron (C 17 H 9 ClF g N 2 0 4 ), also known as /V-[[[3-chloro-4-[l,l,2-trifluoro-2- (trifluoromethoxy)ethoxy]phenyl]amino]carbonyl]- 2,6-difluorobenzamide.
  • the concentration of novaluron present in the spot-on composition effective for the treatment of pest infestations in animals may be as high as between about 15% and 45% (w/w).
  • the spot-on compositions of the present invention may optionally include the N-arylpyrazole compound known as fipronil.
  • Fipronil is a phenylpyrazole acaricide with efficacy against a broad spectrum of tick species and was first disclosed in U.S. Patent No. 5,232,940. Fipronil achieves its efficacy by disrupting the central nervous system by blocking the passage of chloride ions through the GABA receptor and glutamate-gated chloride channels (GluCl), components of the central nervous system. This disruption causes hyperexcitation of contaminated nerves and muscles, which results in eventual death.
  • GluCl glutamate-gated chloride channels
  • Fipronil is also known as 5-amino-l-[2,6-dichloro-4- (trifluoromethyl)phenyl]-4-[(l-R,S)(trifluoromethyl)sulfinyl]-lH-pyrazole-3-carbonitrile, 5- amino-l-(2,6-dichloro-a,a,a-trifluoro-p-tolyl)-4- [(trifluoromethyl) sulfinyl] pyrazole-3- carbonitrile, and fluocyanobenpyrazole [CAS No.
  • Fipronil is generally available as either a liquid or solid crystalline substance or powder. Fipronil typically comprises between about 1% and about 20% (w/w) of the total weight of the spot-on composition. In some embodiments, fipronil comprises about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% (w/w) of the spot-on composition. For example, the amount of fipronil present in the spot-on composition may range from between about 5% to about 15% (w/w) of the total composition, and preferably ranges from between about 7% and about 12% (w/w).
  • the amount of fipronil present in the spot-on composition may range from between about 8% and about 11% (w/w) of the total composition. In an exemplary embodiment, the amount of fipronil present in the composition is 9.8% (w/w) of the total composition.
  • the spot-on compositions of the present invention do not additionally include crystallization inhibitors.
  • the spot-on compositions of the present invention also may comprise a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the paresthesia-reducing agent generally comprises between about 40% to about 90% (w/w) of the spot-on composition.
  • the paresthesia-reducing agent comprises 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40% (w/w) of the total composition.
  • the amount of paresthesia-reducing agent present in the spot-on composition preferably ranges from between about 60% to about 80% (w/w) of the composition.
  • the amount of paresthesia-reducing agent present in the spot-on composition ranges from between about 60% to about 75% (w/w) of the total composition.
  • the amount of paresthesia-reducing agent present in the spot-on composition ranges from between about 70% to about 85% (w/w) of the total composition. In still another embodiment, the amount of organic solvent in the spot-on composition ranges from between about 60% to about 70% (w/w).
  • the spot-on compositions of the present invention may comprise an organic solvent rather than a paresthesia-reducing agent.
  • the organic solvent is defined as a carbon-containing chemical that is capable of dissolving a solid, liquid, or a gas.
  • the solvents should generally have a dielectric constant ranging from about 1 to 40, a low boiling point (less than 100°C), have a density less than the density of water (less than 1.0 at 20°C), and generally be soluble with water.
  • the organic solvent comprises diethylene glycol
  • An organic solvent may comprise between about 55% to about 85% (w/w) of the spot-on composition.
  • the organic solvent comprises 85%, 80%, 75%, 70%, 65%, 60%, or 55% (w/w) of the total composition.
  • the amount of organic solvent present in the spot-on composition may range from between about 60% to about 80% (w/w) of the composition.
  • the amount of organic solvent in the spot-on composition may range from between about 60% to about 75% (w/w) of the total composition.
  • the amount of organic solvent in the spot-on composition may range from between about 70% to about 80% (w/w) of the total composition.
  • the amount of organic solvent in the spot-on composition may range from between about 60% to about 70% (w/w).
  • the spot-on composition may further include an antioxidant.
  • An antioxidant can generally be defined as a compound capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from the original substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that damage cells. Antioxidants terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions by being oxidized themselves.
  • the antioxidant acts as a stabilizer, preventing the various components from degrading by oxidation processes.
  • an antioxidant is incorporated into the current invention it should generally be miscible with the organic solvents described herein. It is preferred that the antioxidant does not cause irritation to the skin of an animal, specifically a dog or cat, when applied to the animal's skin. In addition, the antioxidant may be natural or synthetic.
  • Suitable antioxidants include, but are not limited to, ascorbic acid and its salts, ascorbyl palmitate, ascorbyl stearate, anoxomer, N-acetylcysteine, benzyl isothiocyanate, m-aminobenzoic acid, o- aminobenzoic acid, p-aminobenzoic acid (PABA), butylated hydroxyanisole (BHA), butylated hydro xytoluene (BHT), caffeic acid, canthaxantin, alpha-carotene, beta-carotene, beta-carotene, beta-apo-carotenoic acid, carnosol, carvacrol, catechins, cetyl gallate, chlorogenic acid, citric acid and its salts, clove extract, coffee bean extract, p-coumaric acid, 3,4-dihydroxybenzoic acid, N,N'-diphenyl-p-phenylenediamine (DPPD), d
  • the antioxidants incorporated into the composition encompass all potential salt and ester forms of the antioxidants in addition to the pure forms of the compound.
  • the antioxidant comprises a vitamin E compound such as tocopherol acetate, tocopherol linoleate, tocopherol nicotinate, tocopherol succinate, ascorbyl tocopherol phosphate, dioleyl tocopherol methylsilanol, tocophersolan, and tocopherol linoleate/oleate.
  • the antioxidant comprises tocopherol nicotinate.
  • the antioxidant may comprise less than about 10% (w/w) of the total spot- on composition.
  • the antioxidant comprises about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, or 0% (w/w) of the total composition.
  • the amount of antioxidant present in the spot-on composition may range from between 2% to about 10% (w/w) of the total composition, and preferably the antioxidant ranges from between about 3% to about 6% (w/w) of the total composition.
  • the amount of antioxidant present in the spot-on composition may range from between about 4% to about 6% (w/w) of the total composition.
  • the amount of antioxidant present in the composition is about 5.3% (w/w).
  • the spot-on composition may further include inactive excipients that are added to the composition as a result of their incorporation into the individual active components.
  • the cyphenothrin and ivermectin components of the composition may be provided in a 95% solution, meaning that 95% of the composition volume is active compound including cyphenothrin and ivermectin, and the remaining 5% constitutes inactive excipients that are consequently introduced into the composition, as such the pesticide may not be 100% pure concentrate and may be purchased with other constituents.
  • the inactive excipients include, but are not limited to binders, fillers, non-effervescent disintegrants, effervescent disintegrants, preservatives, diluents, lubricants, pH modifiers, stabilizers, and the like. It should, however, be understood that the inactive excipients are typically incorporated as a portion of the active ingredient components and comprise a small percentage (generally less than 1%) of the total spot-on composition volume, generally not affecting the physical characteristics of the spot-on composition.
  • the active components of the spot-on composition may be provided in the form of pure concentrate (100% concentration) or a diluted composition with additional excipients in the dosage form (i.e. the amount of active ingredient in the composition is less than or equal to 99.99%, and the remainder consists of inactive excipients).
  • additional excipients in the dosage form i.e. the amount of active ingredient in the composition is less than or equal to 99.99%, and the remainder consists of inactive excipients.
  • the volume of active component added to the spot-on composition will need to be adjusted to account for the dilution and to ensure the end spot-on composition comprises the appropriate final concentration of each of the active components.
  • spot- on composition may be provided in a variety of dosage forms including, but not limited to powder, briquettes, liquid solution or suspension, pellets, emulsion, aerosol, cream, gel, ointment, and the like.
  • the spot-on pesticide composition of the current invention can be produced by contacting the various active components of the spot-on composition with one another to produce a spot-on formulation suitable for application to an animal's skin.
  • the current invention encompasses a variety of physical formulations; however, the spot-on compositions of the current invention are generally directed to liquid solutions and suspensions.
  • the formulations of the present invention may be prepared by standard techniques known in the art. For instance, in one embodiment where the desired spot- on formulation is a liquid solution, the composition is produced by bringing the pyrethroid and avermectin components into contact with a paresthesia-reducing agent and then gently heating and stirring the components until dissolved.
  • the various components of the spot-on composition may be contacted and mixed with one another in any order desired, so long as solution is adequately stirred and mixed.
  • the spot-on composition may vary depending upon the physical characteristics desired.
  • the spot-on composition should be capable of application to the skin of an animal and provide adequate stasis to allow the active components of the spot-on composition to be absorbed by the host animal.
  • the spot- on compositions of the present invention have low viscosity. Viscosity is the measurement of flow resistance due to internal friction within the fluid, and is measured in centistokes (cSt). A lower cSt measurement means the fluid will flow with less resistance, because of minimal molecular friction within the fluid. The lower the viscosity the faster the fluid will flow. High viscosity substances are liquids that are thick and gelatinous in nature with slow flow.
  • the spot-on compositions of the present invention typically have a viscosity ranging from about 0.01 mm /second to about 100 mm /second. In a more preferred embodiment, the spot-on composition has a viscosity ranging from about 1 mm /second to about 30 mm /second. In a further preferred embodiment, the spot- on composition has a viscosity ranging from about 4 mm /second to about 20 mm /second.
  • a basic spot-on composition of the present invention includes a pyrethroid at a concentration ranging between about 0.25% and about 60% (w/w), a macrocyclic lactone at a concentration ranging between about 0.01% and about 5% (w/w), and an effective amount of a paresthesia-reducing agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol succinate, tocopherol nicotinate, and combinations thereof.
  • the basic spot-on composition it is preferable to use between about 15% to about 30% (w/w) pyrethroid, about 1% to about 5% (w/w) macrocyclic lactone, and about 50% to about 80% (w/w) paresthesia-reducing agent, depending on the type of animal to be treated.
  • the basic spot- on composition may also additionally include an IGR at a concentration ranging between 1% and about 20% (w/w) of the composition, preferably at a concentration ranging between about 2% to about 12% (w/w) of the total composition. More preferably, the IGR is present in the composition at a concentration ranging between 4% and 12% (w/w) of the total composition.
  • the basic spot-on composition may further include an antioxidant at a concentration ranging between 1% and about 10% (w/w) of the total composition, preferably at a concentration ranging between about 4% and about 6% (w/w) of the total composition.
  • the present invention further embodies a method of killing heartworm, pest pupae and adults on an animal comprising administering a localized cutaneous application between the shoulders of the animal, a spot-on composition comprising between about 0.25% to about 60% (w/w) pyrethroid and between about 0.01% to about 5% (w/w) macrocyclic lactone.
  • the method of the using the composition of the present invention preferably involves the localized administration of the basic spot-on composition, which composition preferably comprises between about 15% to about 30% (w/w) pyrethroid, about 0.05% to about 5% (w/w) macrocyclic lactone, and may additionally include between about 4% to about 12% (w/w) of an IGR.
  • compositions and method according to this invention are intended for application to animals, in particular dogs and cats, and are generally applied by deposition onto the skin ("spot-on” or "pour-on” application).
  • Treatment typically comprises a localized application over a surface area of less than 10 cm 2 , especially of between 5 and 10 cm 2.
  • the spot-on composition should be applied to an area where the animal cannot lick the application area, as licking of the application area may lead to transient adverse effects, such as excessive salivation.
  • application is preferred at two points and preferably localized between the animal's shoulders.
  • the composition diffuses, in particular over the animal's entire body, and then dries without crystallizing or modifying the appearance (in particular absence of any whitish deposit or dusty appearance) or the feel of the animal's fur.
  • the method of the current invention is directed to application of the spot-on composition to the skin of the animal every four weeks to ensure continuous treatment and prevention of pest infestation.
  • the active constituents are applied to the host animal together in a single formulation.
  • the method of killing insects is carried out such that the spot-on composition is applied in a volume sufficient to deliver a dosage of the active pyrethroid component ranging from about 0.1 mg/kg to about 40 mg/kg of host animal body weight.
  • the dose of pyrethroid ranges from about 0.5 mg/kg to about 20 mg/kg of host animal body weight.
  • the spot-on composition application comprises a volume sufficient to deliver a pyrethroid dose ranging from about 0.5 mg/kg to about 10 mg/kg of host animal body weight.
  • the method of killing insects is carried out such that the spot-on composition further comprises an IGR, and is applied in a volume sufficient to deliver a dosage of the insect growth regulating active component ranging from about 0.1 mg/kg to about 40 mg/kg of host animal body weight.
  • the dose of insect growth regulator ranges from about 0.2 mg/kg to about 20 mg/kg of host animal body weight.
  • the spot-on composition application comprises a volume sufficient to deliver an insect growth regulator dose ranging from about 0.5 mg/kg to about 10 mg/kg of host animal body weight.
  • the composition provided herein is safe for use in puppies as young as 6 weeks old, breeding and nursing animals, and avermectin- sensitive collies.
  • the dosage ranges provided above are approximate values that may vary within a broad range.
  • the variance in dose is due to the fact that, in practice, the spot-on composition will be administered in defined doses and volumes to animals within a certain range of weights.
  • the dosage actually applied to the animal may vary by a factor ranging from 0.1 to 10 relative to the preferred dose, without imparting any additional risks pertaining to toxicity or decreased efficacy.
  • the components of the composition are effective against a wide variety of pests and parasites, the composition is especially developed for the treatment of fleas (including the Ctenocephalides species), ticks (the Rhipecephalus, Ixodes, and Trichodectes species), heartworms (including the Dirofilaria immitis species), ear mites (including the Otodectes cynotis species), and Sarcoptes spp. that causes mange in animal.
  • fleas including the Ctenocephalides species
  • ticks the Rhipecephalus, Ixodes, and Trichodectes species
  • heartworms including the Dirofilaria immitis species
  • ear mites including the Otodectes cynotis species
  • Sarcoptes spp. that causes mange in animal.
  • hookworms including Ancylostoma species and Uncinaria species
  • roundworms including Toxascaris lenoina, Toxocara canis, and Toxocara cati species
  • whipworms including Trichuris vulpis and Trichuris campanula species
  • tapeworms including Dipylidium caninum, Taenia species, Echinococcus granulosus and Echinococcus multiocularis, Diphyllobothrium latum and Spirometra mansonoides species.
  • the frequency of application may be varied according to the needs of the individual animal, as well as the severity of infestation.
  • the treatment of parasites may be repeated as often as once weekly, or may be reserved for one-time acute treatments of pest infestation or flare-ups. In one embodiment of the current invention, the treatment of parasites may be repeated about every four weeks, five weeks, or six weeks.
  • the spot-on composition is applied to the host animal for a one-time treatment of the pest infestation.
  • parasites are treated at a frequency ranging from one to four weeks, with treatment every two weeks being preferred.
  • the spot-on composition is applied on a one-time basis for the treatment of parasites infestation.
  • the terms “about” and “approximately” designate that a value is within a statistically meaningful range. Such a range can be typically within 20%, more typically still within 10%, and even more typically within 5% of a given value or range. The allowable variation encompassed by the terms “about” and “approximately” depends on the particular system under study and can be readily appreciated by one of ordinary skill in the art.
  • w/w designates the phrase “by weight” and is used to describe the concentration of a particular substance in a mixture or solution.
  • mL/kg designates milliliters of composition per kilogram of body weight.
  • the term “treatment” or “treating” of a condition includes inhibiting an existing condition or arresting its development; or ameliorating or causing regression of the condition.
  • the term “preventing” or “prevention” of a condition, such as insect or pest infestation includes substantially blocking or inhibiting the development or growth of a condition before it starts. Compositions that treat or prevent infestations herein will preferably exhibit at least 90% efficacy.
  • pesticide or “pesticidal” refers to an agent or a composition comprising an agent that is capable of preventing, reducing or eliminating pest infestations.
  • Preferred pesticides of the present invention include cyphenothrin and ivermectin.
  • IGR insect growth regulator
  • animal refers to a mammal, specifically a companion animal, including but not limited to dogs, cats, rabbits, ferrets, horses, and hamsters.
  • the term “pest” and “insect” refers to any ectoparasite, including but not limited to fleas, ticks, flies, keds, mosquitoes, and mites.
  • paresthesia-reducing agent refers to an agent or combination of agents that reduces or eliminates paresthesia and is selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof.
  • a spot-on formulation was prepared in accordance with Table 1.
  • the purified diethylene glycol monoethyl ether and the tocopherol nicotinate were charged to a vessel and heated to a temperature of 50°C (about 1 hour). Once heated, the cyphenothrin, the moxidectin, and the methoprene were charged to the vessel and all components were mixed until a homogenous solution was formed (about 1 hour).
  • composition prepared exhibited at least 90% efficacy against pests

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de pesticide pour application locale pour animaux, spécifiquement des mammifères, en particulier des chiens, cette composition comprenant une combinaison d'un pyréthroïde et d'une lactone macrocyclique choisie parmi l'avermectine, l'ivermectine, la sélamectine, la moxidectine, la milbémycine et toute combinaison de celles-ci, et éventuellement du fipronil et/ou un régulateur de croissance d'insecte, à des doses et dans des proportions qui sont efficaces au plan parasiticide contre une variété d'insectes et de nuisibles, et dans une formulation qui est pratique pour l'application locale sur la peau de l'animal, de préférence localisée sur une petite surface.
PCT/US2013/035498 2012-04-05 2013-04-05 Composition de pesticide pour application locale contenant un pyréthroïde et une lactone macrocyclique WO2013152315A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620693P 2012-04-05 2012-04-05
US61/620,693 2012-04-05

Publications (1)

Publication Number Publication Date
WO2013152315A1 true WO2013152315A1 (fr) 2013-10-10

Family

ID=49301097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/035498 WO2013152315A1 (fr) 2012-04-05 2013-04-05 Composition de pesticide pour application locale contenant un pyréthroïde et une lactone macrocyclique

Country Status (1)

Country Link
WO (1) WO2013152315A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009219A1 (fr) * 2015-07-10 2017-01-19 Ceva Sante Animale Combinaisons de néonicotinoïde et de pyréthrinoïde pour lutter contre la propagation de dirofilariose
WO2019101971A1 (fr) * 2017-11-23 2019-05-31 Ceva Sante Animale Composition pour le traitement d'infestations parasitaires
US11134685B2 (en) 2015-07-24 2021-10-05 Ceva Santé Animale Compositions and uses thereof for controlling ectoparasites in non-human mammals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137627B1 (fr) * 1983-08-12 1992-01-22 Pitman-Moore Australia Limited Formulation pour application par versement pour lutter contre les parasites
US20010022111A1 (en) * 2000-02-23 2001-09-20 Ritchie Norman E. Vehicle shifter

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137627B1 (fr) * 1983-08-12 1992-01-22 Pitman-Moore Australia Limited Formulation pour application par versement pour lutter contre les parasites
US20010022111A1 (en) * 2000-02-23 2001-09-20 Ritchie Norman E. Vehicle shifter

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009219A1 (fr) * 2015-07-10 2017-01-19 Ceva Sante Animale Combinaisons de néonicotinoïde et de pyréthrinoïde pour lutter contre la propagation de dirofilariose
US10952988B2 (en) 2015-07-10 2021-03-23 Ceva Santé Animale Methods for controlling the spread of dirofilariosis
US11134685B2 (en) 2015-07-24 2021-10-05 Ceva Santé Animale Compositions and uses thereof for controlling ectoparasites in non-human mammals
WO2019101971A1 (fr) * 2017-11-23 2019-05-31 Ceva Sante Animale Composition pour le traitement d'infestations parasitaires
US11872208B2 (en) 2017-11-23 2024-01-16 Ceva Sante Animale Composition for treating parasites infestations

Similar Documents

Publication Publication Date Title
AU2014213490B2 (en) Spot-on pesticide composition
US9801375B2 (en) Spot-on pesticide composition
CA2903543A1 (fr) Composition antiparasitaire a application localisee ("spot-on") comprenant un neonicotinoide et un pyrethroide
US20130231371A1 (en) Spot-on pesticide composition containing a pyrethroid and macrocyclic lactone
WO2013152315A1 (fr) Composition de pesticide pour application locale contenant un pyréthroïde et une lactone macrocyclique
AU2012278286B2 (en) Agents for the control of parasites on animals
AU2013272258B2 (en) Methods for preventing flea allergy dermatitis in companion animals
US10172359B2 (en) Solvent system for use with spot-on pesticide compositions
USRE45874E1 (en) Spot-on pesticide composition
AU2014233558B2 (en) Spot-on pesticide composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13771765

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13771765

Country of ref document: EP

Kind code of ref document: A1